High p95HER2/HER2 Ratio Associated With Poor Outcome in Trastuzumab-Treated HER2-Positive Metastatic Breast Cancer NCCTG N0337 and NCCTG 98-32-52 (Alliance)

BACKGROUND: p95HER2 is a truncated form of human epidermal growth factor receptor 2 (HER2) that confers resistance to trastuzumab in vitro, but clinical results have been conflicting to date. Given that p95HER2 levels correlate with total HER2 expression levels, which confer better outcomes, we soug...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Chumsri, Saranya, Sperinde, Jeff, Liu, Heshan, Gligorov, Joseph, Spano, Jean-Philippe, Antoine, Martine, Aspitia, Alvaro Moreno, Tan, Winston, Winslow, John, Petropoulos, Christos J, Chenna, Ahmed, Bates, Michael, Weidler, Jodi Marie, Huang, Weidong, Dueck, Amylou, Perez, Edith A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2018
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6314664/
https://ncbi.nlm.nih.gov/pubmed/29530935
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-17-1864
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados